2. Academic Validation
  3. Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay

  • NPJ Breast Cancer. 2025 Feb 17;11(1):17. doi: 10.1038/s41523-025-00734-x.
Zofia M Komar 1,  Nicole S Verkaik 1 2,  Ahmed Dahmani 3,  Elodie Montaudon 3,  Roland Kanaar 1 2,  Adriaan B Houtsmuller 4,  Agnes Jager 5,  Elisabetta Marangoni 3,  Dik C van Gent 6 7
Affiliations

Affiliations

  • 1 Department of Molecular Genetics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • 2 Oncode Institute, Erasmus MC, Rotterdam, The Netherlands.
  • 3 Translational Research Department, Institut Curie, PSL University, Paris, France.
  • 4 Erasmus Optical Imaging Center and Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.
  • 5 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • 6 Department of Molecular Genetics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. d.vangent@erasmusmc.nl.
  • 7 Oncode Institute, Erasmus MC, Rotterdam, The Netherlands. d.vangent@erasmusmc.nl.
PMID: 39962055 DOI: 10.1038/s41523-025-00734-x
Abstract

Breast Cancer is the most common Cancer amongst women worldwide, however clinically validated chemotherapy response biomarkers that can accurately predict treatment response in patients are largely lacking. Therefore, in this study, functional paclitaxel and eribulin ex vivo sensitivity assays were developed. Patient derived xenograft (PDX) models were used to compare the ex vivo predicted treatment outcome with the sensitivity of mice in vivo. We validated the previously developed sensitivity assay for paclitaxel, which is based on the ratio between replicating (EdU) and mitotic (phospho-Histone H3; pH3) cells as a proxy for blocked mitosis. The assay showed 90% correlation between the ex vivo and in vivo response to paclitaxel treatment in the PDX models. We propose the term REMIT (REplication MITosis) assay and show that it is also a suitable test to predict eribulin sensitivity. The reproducibility of the REMIT assay for paclitaxel and eribulin was determined to be 80% and 83%, respectively. These results justify further clinical validation of the REMIT assay in breast Cancer patients.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z